2020
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. Journal Of Biological Chemistry 2020, 295: 14379-14390. PMID: 32796035, PMCID: PMC7573269, DOI: 10.1074/jbc.rev120.008387.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSodium-glucose cotransporter 2SGLT2 inhibitorsEuglycemic ketoacidosisGlucose reabsorptionTherapeutic promiseSGLT2 inhibitor therapyLower plasma glucose concentrationsModest weight lossGlucose-lowering agentsRenal glucose reabsorptionType 2 diabetesType 1 diabetesPlasma glucose concentrationGlucose concentrationBlood glucose concentrationHeart failureInhibitor therapyAtrial fibrillationCardiovascular diseaseCotransporter 2Preclinical studiesHealthy personsClinical utilityDiabetes managementProximal tubules
2018
Mechanism by Which Dapagliflozin Induces Euglycemic Ketoacidosis in Rats
PERRY R, SONG J, WANG Y, SHULMAN G. Mechanism by Which Dapagliflozin Induces Euglycemic Ketoacidosis in Rats. Diabetes 2018, 67 DOI: 10.2337/db18-254-or.Peer-Reviewed Original ResearchSodium-glucose transport protein 2 inhibitorsHepatic glucose productionEffect of dapagliflozinEuglycemic ketoacidosisHepatic ketogenesisVolume depletionGlucose productionPlasma catecholaminesWhite adipose tissue lipolysisPlasma glucagon concentrationsExtracellular volume depletionPlasma insulin levelsAdipose tissue lipolysisPlasma insulin concentrationHepatic acetyl-CoA contentNormal Sprague-DawleyICV injectionWAT lipolysisInsulin levelsFurosemide treatmentGlucagon concentrationsAcetyl-CoA contentSaline infusionTissue lipolysisInsulin concentrations